Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When people first read about adipose-derived stem cell therapy, the natural question is what the treatment might offer. A question that deserves equal attention is who it may not suit. In regenerative medicine, deciding whether to proceed is a medical judgment made by a physician, and it starts with a careful screening conversation. This article explains what that conversation usually covers, so that international patients considering Grand Green Osaka Umekita Clinic in Osaka can prepare thoughtful questions.
In short, there is no universal checklist that applies to everyone. Whether this therapy is appropriate depends on your medical history, current health and goals, and it can only be determined by a doctor after an in-person or remote consultation. Nothing in this article is a substitute for that assessment.
What adipose-derived stem cell therapy involves
Adipose-derived stem cell therapy is a regenerative treatment in which mesenchymal stem cells are taken from a very small amount of your own fat tissue, cultured and expanded at a specialized facility, and then returned to your body by intravenous infusion. Fat collection is performed under local anesthesia on an outpatient basis. Because the cells come from you, the therapy is described as autologous, which is generally associated with a lower risk of rejection than donor cells, although it does not remove all risks.
Mesenchymal stem cells have been reported in research to secrete anti-inflammatory substances and growth factors that may support the repair of damaged tissue. Studies are ongoing worldwide, and the evidence varies by condition. For that reason, a responsible consultation treats the therapy as an option to be examined, not as an assured outcome.
Why screening matters before any treatment is planned
The therapy involves two procedural steps: a small fat collection and an intravenous infusion weeks later, once the cells have been cultured. Each step carries its own considerations, and a patient’s general health can influence both. Screening helps the physician decide whether the potential benefits are reasonable to discuss in your particular situation, and whether other approaches, including standard medical care, should come first.
Screening is also a chance for you to ask questions. A clinic that explains its reasoning, including reasons it might advise against treatment, is giving you useful information for your decision.
Topics the doctor may raise during the consultation
The exact content differs between patients, but a consultation about this therapy may touch on the following areas.
- Your main concern and goals, and whether they match what the therapy has been studied for
- Your past and current illnesses, including any history of cancer, infections, blood clotting problems or immune-related conditions
- Medications and supplements you take, especially blood thinners, and any allergies, including to local anesthetics
- Previous surgeries or treatments, and the results of recent tests you can share
- Whether you are pregnant, planning pregnancy or breastfeeding
- Your ability to attend the collection visit, the later infusion, and any follow-up
These items are examples of what a physician may consider, not a fixed list of exclusions. Some factors may lead the doctor to suggest additional tests, a delay, or a different path altogether.
Why this is a medical decision, and what the Japanese framework adds
In Japan, treatments of this kind are provided under the Act on the Safety of Regenerative Medicine, which requires a clinic to submit a regenerative medicine provision plan and to manage cell processing and treatment according to defined procedures. Adipose-derived stem cell therapy at the clinic is offered as a self-pay (non-insured) treatment, so it is not covered by Japanese public health insurance.
This framework governs how treatment is provided and reviewed, but it does not mean that every person is a suitable candidate, nor does it predict any individual result. Patients should ask the clinic how its provision plan applies to them and what information they will receive in writing before consenting.
Practical questions for international patients
If you are traveling from abroad, screening has a practical side as well. Because the process includes fat collection, a culture period and a later infusion, you may need to plan more than one visit or discuss how follow-up will work after you return home. It helps to bring or send in advance an English summary of your medical history, a list of medications with their generic names, and recent test results.
- Which of my records should be translated or sent before the consultation?
- What tests might be needed, and where can they be done?
- What would make you advise against or postpone this therapy for me?
- What are the possible risks and side effects of fat collection and infusion?
- What is the total cost, what does it include, and when is it due?
- How will my regular doctor at home be informed and involved?
The clinic provides an information page for international patients, and multilingual support can be arranged to make these conversations easier. Please confirm the current details of language support, fees and treatment schedules directly with the clinic.
Putting it together
Adipose-derived stem cell therapy is an option worth understanding, but the more important first step is an honest screening discussion with a doctor. Expect questions about your health history, an explanation of risks and side effects, a clear statement of costs as a self-pay treatment, and an open conversation about whether the therapy fits your situation or whether other care should come first.
If you are considering regenerative medicine in Osaka, preparing your records and questions in advance can make the consultation more productive. Fees, risks, side effects and suitability should all be confirmed with a physician at Grand Green Osaka Umekita Clinic before you decide.
- Doctor's screeningSuitability is a medical decision
- Health history reviewIllnesses, medications, allergies
- Self-pay treatmentConfirm costs in advance
- Ask about risksRisks and side effects
This figure is a conceptual diagram summarizing the article
References
- PMC: Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial. (2021)
- PMC: Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)
- PMC: Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. (2026)
- PMC: "Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial". (2022)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.